Background: Inflammatory bowel disease impairs patients' health related quality of life (HRQOL). AntiTNFα agents control disease activity effectively. An ambitious goal of treatment is to achieve the normalization of health. This can be assessed by using a cut-off scoring threshold of the IBDQ-36 questionnaire. It has not been established if antiTNFα treatment is able to restore to normal patients' HRQOL. Aims: To determine whether patients with Crohn's disease (CD) and ulcerative colitis (UC) in clinical remission after one year treatment with antiTNFα agents achieve normalization of their HRQOL. Methods: Observational and cross-sectional study in patients treated with antiTNFα for one year and in sustained clinical remission. Patients completed the specific questionnaire IBDQ-36. Complete restoration of health was considered achieved when global score of IBDQ-36 was higher than 209 points. Results: 54 patients (43 with CD and 11 with UC) were included. Thirty patients received adalimumab and 24 infliximab. Median global score of the IBDQ-36 was 231, without differences between CD and UC (228 vs 235 respectively, p = ns). Normalization of HRQOL was achieved in all 11 UC patients and in 29 out of 43 CD patients (67%). In our sample population, restoration of health was significantly more frequent in UC than in CD (p b 0.05). Conclusions: One-year clinical remission induced by antiTNFα treatment restores perception of health to normal in most patients with IBD.
Introduction
Inflammatory bowel disease (IBD), including Crohn's disease (CD) and ulcerative colitis (UC), is a prevalent immunoinflammatory condition 1 that, due to its characteristics of chronicity, symptoms, complications, need of a maintained treatment with potential adverse effects, dependence of medical visits, surgical interventions, among others, cause a profound impact in patient's health. Due to these reasons, IBD is considered a disabling disease 2 that impairs all domains of life, [3] [4] [5] that impact on patient's health related quality of life (HRQOL). 6 There are different disease associated variables that influence the patient's HRQOL, being the activity of the disease one of the most important. 7 Because it has been shown that effective treatment, independently of whether it is medical or surgical, 8 is able to improve HRQOL, nowadays in clinical trials, and also in clinical practice, one of the most important goals of treatment is to improve patient's perception of health or HRQOL. The improvement achieved in HRQOL by efficacious treatment is maintained over time in parallel with the clinical therapy. 9 However, the intrinsic subjective nature of the HRQOL justifies the fact that it is not equivalent to the activity of the disease. In this sense, the observations are relevant that although patients achieve clinical remission, the scoring of generic HRQOL questionnaires can be lower than in the general population of similar age and sex. 10 In addition, definition of clinical remission according to standardized clinical activity indexes such as the Mayo score do not correlate perfectly with patients' perception.
11 Discrepancies between HRQOL and clinical activity of the disease are logical because they are different measurements, since HRQOL or patients' perception of health status is entirely subjective, and the activity index is more objective. As a consequence of the difference of both concepts, clinical remission is not a synonym of good HRQOL. For that reason, to recognize the consequences of IBD one not only has to measure the clinical activity but also it is very important to determine HRQOL.
The efficacy of treatment for IBD is determined according to whether a cut-off on clinical indexes scoring is reached. However, in terms of HRQOL efficacy of a medical intervention, it is usually determined depending on a statistical increase in the scoring of questionnaires. To this purpose, the most commonly used instrument to measure IBD patients' HRQOL is the Inflammatory Bowel Disease Questionnaire (IBDQ). This is a responsive instrument that reflects rapid changes in HRQOL and even allows a cut-off value for remission. 12 In the evaluation of the effect of treatment on patient's HRQOL an ambitious approach is not only to improve the punctuation of the questionnaires, but to restore health perception to normality. There is little information available related to the definition of the punctuation threshold to be reached to consider that the patient's HRQOL has normalized. For the 36 items (36-item) version of the IBDQ a normality threshold, equivalent to a normalized HRQOL, has been calculated. Scores equal or superior to 209 in the 36 items (36-item) version of the IBDQ questionnaire correspond to a quality of life equal to that perceived by the general population of reference. 13 Based on the lack of evidence if clinical remission is equivalent to normalization of health, the purpose of the present study has been to determine in a group of patients with stable clinical and biological remission induced by antiTNFα treatment during one year, whether perception of health has been restored to normal according to the pre-established normality threshold of the IBDQ.
Materials and methods

Patient selection
An observational, cross-sectional study was carried out in patients with either UC or CD treated with antiTNFα agents for one year. The diagnosis was based on conventional clinical, endoscopic, radiologic and histological criteria. 14 To be included, all patients were in stable (more than 6 months) clinical and biological remission. Clinical remission was considered when scoring of simplified Colitis Activity Index (CAI) was lower than to 6 15 for UC or a Harvey-Bradshaw score lower (than) to 3 16 for CD. Biological remission was considered when seric reactive protein C was in the normal range (b 0.5 mg/dl in our laboratory). All patients responded to biologic antiTNFα treatment induction, and were on maintenance treatment with either adalimumab or infliximab at the usual doses (adalimumab 40 mg/eow or infliximab 5 mg/kg/eom) for one year. All patients are examined every two months to determine clinical and biological activity. Basic demographic and clinical data were collected.
HRQOL assessment
The patients' HRQOL was assessed using the specific 36 items (36-item) IBDQ questionnaire. This is a self-administered questionnaire that has previously been translated and validated for its use in Spanish. 17 The 36 items (36-item) version of the IBDQ 18 contains 36 items grouped into five domains of health (bowel symptoms, systemic symptoms, functional impairment, social impairment, and emotional function). Responses are scored on a 7-point Likert scale, in which 7 corresponds to the highest level of functioning. The instrument produces five dimension scores and an overall IBDQ score ranging from 36 to 252, where a higher score reflects better HRQOL. According to previously validated criteria, perception of health was considered restored to normality when global score of the IBDQ-36 was higher than 209 points. 13 
Statistical analysis
Statistical analysis was carried out by the computerized program GraphPad Instat version 3.10. Results are expressed as absolute numbers, percentages or medians [percentile 25-percentile 75] as necessary. To determine differences between qualitative variables, the Fisher's exact test was performed. To determine differences between quantitative variables, corresponding two-tailed nonparametric tests were performed. p values lower to 0.05 were accepted as statistically significant.
Results
Patient characteristics
From a total of 163 patients receiving biological treatment in our Unit, fifty-four patients -43 with CD (79%) and 11 with UC (21%) -met the criteria to be included. Biological treatment included adalimumab in 30 cases (26 with CD and 4 with UC) or infliximab in 24 cases (17 with CD and 7 with UC). Because of the different indications of treatment, the use of adalimumab was more frequent in CD than in UC. Indication for biological treatment was disease refractory to corticosteroids or immunosuppressants in 43 patients and perianal fistula in 11 patients. Most patients (89.0%) received concomitantly immunomodulators, azatioprine in 43 cases (89.5%) and methotrexate or mycofenolate in the five remainder (remaining) patients. The clinical characteristics of patients are summarized in Table 1 . Both groups of patients share similar clinical characteristics. As expected, because of the inclusion criteria, reactive protein C was normal and clinical activity indexes scored low. 
Quality of life in inactive IBD
Restoration of health in inactive IBD
Normalization of HRQOL was achieved in 74% of patients (Table 3) , i.e. in all 11 patients with UC and in 29 out of 43 CD patients. The proportion of normalization of HRQOL was Apart from the type of disease, there were no other clinical or demographic variables significantly associated with normalization of HRQOL (Table 3 ), i.e. able to predict restoration of health in patients in clinical remission. However, our current data in this small patient sample suggest that restoration of health in patients in remission is more common in young-adult non-smoker females with longstanding colitis. Socio-demographic variables (Table 4) that have been determined (marital status, working status, educational level) are similar for patients that reach restoration of health as for those who did not.
Discussion
In normal practice and also in controlled therapeutic trials, the assessment of a clinical response is based in the improvement of the HRQOL, defined as an increase in the scoring of the questionnaires. This improvement might not be clinically significant or relevant to the patient, and it should be reinforced with the achievement of a restoration of a normal perception of health. Results of our study demonstrate that long term effective treatment with biological antiTNF agents improves clinical status lowering the scoring of clinical indexes and it was in parallel with an improvement of HRQOL. In addition, our study goes further on and elucidates if patients that achieve maintained clinical remission restored to normal their perception of health. It has been previously shown that an IBDQ-36 punctuation score above 209 reflects a quality of life equivalent to that of the general population of reference. 13 The present study was not designed to evaluate the improvement of HRQOL when patients reach clinical remission but to determine whether the stable control of the IBD with biological antiTNFα treatment is associated with a normalization of perception of health as determined by an IBDQ-36 score over the previously validated cutoff. Thus, the IBDQ-36 was administered to patients in clinical and analytical remission after one year of conventional treatment with adalimumab or infliximab. Biological antiTNFα treatment was chosen because it is commonly accepted that it is an effective treatment that allows a sustained clinical (median score of clinical indices of 0-1) and biological (RCP within normal range) response. Patients were not separated by diagnosis, UC vs CD, because punctuation of global HRQOL questionnaire was not different from UC and CD and because the used cutoff is independent of the diagnosis of UC or CD in the validation study. Dimensional analysis of IBDQ-36 showed that most dimensions were independent of the diagnosis, although two dimensions of the questionnaire differ, functional and social affectation. However, median differences in these two dimensions do not seem clinically relevant.
Our results show that although all patients were clinically asymptomatic, the HRQOL was not restored to normality in up to 26% of patients, implying that some burden of disease was still felt by this subgroup of patients. These findings further add to the concept that HRQOL is not equivalent nor exchangeable with clinical activity and that although an effective treatment improves HRQOL, it is not always the case that the patient's perception of health is reestablished to normal (meaning normal as that expressed by the general population). Although similar findings have been suggested using generic questionnaires, the fact generic questionnaires reflect poorly the repercussion of a specific disease and that they are not as sensitive as specific questionnaires, has justified investigating normality threshold criteria of a fully specific questionnaire. The innovation of the present study is to determine whether HRQOL of patients with IBD (assessed by the specific questionnaire IBDQ-36) is restored as compared with the normality defined by the general population.
The purpose and design of the study was not to compare the effect of different treatments on the restoration of health of IBD patients. We selected patients with good clinical response to antiTNF α treatment for one year because we considered that it is a sufficiently long enough period of time to obtain a stable response. However, from the results of the present study it can not be resolved whether restoration of health is maintained for longer periods of time. Neither was it the objective of the study to determine if the HRQOL improves with the treatment, which justifies that we have not compared the scores of the IBDQ-36 before and after the treatment. This has been repeatedly published in most therapeutic clinical trials.
In conclusion, having previously defined a normality cutoff value for the IBDQ-36, this study tested whether effective biological antiTNFα treatment normalizes HRQOL to the levels perceived by the general population of reference. Results of the present study demonstrate that most patients with sustained response to adalimumab or infliximab normalize their perception of health. However, a group of patients, mainly affected by Crohn's disease, do not restore their HRQOL to normal. If restoration of health is accepted as the final goal of treatment, this observation challenges the current way of assessing success in the management of patients with inflammatory bowel disease.
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